Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics (SPRO)
:SPRO
SPRO Stock Chart & Stats
$2.26
-$0.03(-2.91%)
At close: 4:00 PM EST
$2.26
-$0.03(-2.91%)
Day’s Range― - ―
52-Week Range$0.51 - $3.22
Previous CloseN/A
Volume61.58K
Average Volume (3M)462.72K
Market Cap
$128.45M
Enterprise Value$60.54M
Total Cash (Recent Filing)$48.62M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Last Dividend Ex-Date
Sep 16, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding56,339,294
10 Day Avg. Volume325,487
30 Day Avg. Volume462,716
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.16
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit-0.84
Enterprise Value/Ebitda-1.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$20.10M
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe cash reserves of $48 million are expected to support operational expenses until 2028, providing a lengthy financial runway.
Partnership MilestonesSPRO will receive up to ~$540M total in development, sales, and commercial milestones and low single- to low double-digit tiered royalties on net product sales from GSK.
Trial SuccessThe Phase 3 trial of tebipenem in complicated urinary tract infections met its primary endpoint early, showing strong efficacy and leading to an early stop of the trial.
Bears Say
Financial LossSpero Therapeutics reported a net loss of $7.4 million, highlighting ongoing financial challenges despite potential future revenues.
Reduced Milestone PaymentSPRO will now not receive the full $150M but a prorated amount closer to ~$96M due to the trial stopping early, driving lower R&D costs.
Spero Therapeutics News
SPRO FAQ
What was Spero Therapeutics’s price range in the past 12 months?
Spero Therapeutics lowest stock price was $0.51 and its highest was $3.22 in the past 12 months.
What is Spero Therapeutics’s market cap?
Spero Therapeutics’s market cap is $128.45M.
When is Spero Therapeutics’s upcoming earnings report date?
Spero Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 110 days.
How were Spero Therapeutics’s earnings last quarter?
Spero Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.12.
Is Spero Therapeutics overvalued?
According to Wall Street analysts Spero Therapeutics’s price is currently Overvalued.
Does Spero Therapeutics pay dividends?
Spero Therapeutics pays a Quarterly dividend of $0.015 which represents an annual dividend yield of N/A. See more information on Spero Therapeutics dividends here
What is Spero Therapeutics’s EPS estimate?
Spero Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Spero Therapeutics have?
Spero Therapeutics has 56,339,294 shares outstanding.
What happened to Spero Therapeutics’s price movement after its last earnings report?
Spero Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.23%.
Which hedge fund is a major shareholder of Spero Therapeutics?
Currently, no hedge funds are holding shares in SPRO
Spero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
SPRO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $111.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 49.0%
Last 30 Days ▲ 49.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.22%
12-Months-Change
Fundamentals
Return on Equity
-95.29%
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Spero Therapeutics
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections. The company focuses on its proprietary platform in developing a pipeline of therapeutics to address critical unmet medical needs, particularly in the area of gram-negative bacterial infections. Spero's core products include SPR994 (tebipenem HBr), an oral antibiotic candidate for treating complicated urinary tract infections, and SPR720, an oral antibiotic candidate for treating non-tuberculous mycobacterial pulmonary disease.
SPRO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant achievements, particularly the successful Phase III trial for Tebipenem HBr and the improved financial metrics. However, challenges remain in the SPR720 program. Overall, the positive developments notably outweigh the negative aspects.View all SPRO earnings summariesSPRO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Milestone Pharmaceuticals
―
Korro Bio
―
Connect Biopharma Holdings
―
Tenaya Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
8.15% Insiders
4.52% Mutual Funds
10.56% Other Institutional Investors
73.70% Public Companies and
Individual Investors